Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
Related press release
JANX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1. Registration Statement (Form S-3 No. 333-266720) of Janux Therapeutics, Inc., and
2. Registration Statements (Form S-8 Nos. 333-263712 and 333-257039) pertaining to the 2017 Equity Incentive Plan (Prior Plan), the 2021 Equity Incentive Plan, and the 2021 Employee Stock Purchase Plan of Janux Therapeutics, Inc.;
of our report dated March 10, 2023, with respect to the financial statements of Janux Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2022.
/s/ Ernst & Young LLP
San Diego, California
March 10, 2023